VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT), a pure-play sector fund that has quietly compounded wealth for long-term investors while offering insulation from economic cycles that most equity sectors can’t match.

What VHT Is Actually Built to Do

VHT tracks the MSCI US Investable Market Index (IMI)/Health Care 25/50, capturing the full breadth of U.S. healthcare from mega-cap pharmaceutical giants down to small-cap biotechs. The fund holds over 500 positions, with 99.3% of assets in healthcare. This is not a blended or thematic fund. It is a concentrated sector bet with wide diversification within that sector.

The return engine is straightforward: underlying businesses generate cash flows from drug sales, medical procedures, insurance premiums, and diagnostics. There are no options overlays, no leverage, no complex derivatives. VHT’s 4% annual portfolio turnover reflects a true buy-and-hold posture, and its expense ratio of just 0.09% means costs are essentially a non-factor over time.

The top holdings read like a who’s who of global healthcare. Eli Lilly sits at 12.5% of the fund, followed by Johnson & Johnson at 8.8%, AbbVie at 6.1%, Merck at 4.6%, and UnitedHealth Group at 3.9%. The top 10 positions together represent roughly 45% of the portfolio, so Eli Lilly’s trajectory alone has an outsized impact on VHT’s performance.

The Performance Reality Check

VHT has delivered real long-term gains, but investors need to understand what they gave up compared to the broad market. Over the past decade, VHT returned about 158%. Over the same period, the total U.S. stock market returned nearly 215%. Healthcare compounded wealth, but it lagged meaningfully.

The five-year picture reinforces this gap. VHT gained about 28% over five years, while the total market climbed roughly 57%. Year to date in 2026, VHT is down about 5%, slightly worse than the broad market’s 3% decline. The defensive reputation of healthcare hasn’t fully materialized against a market powered by technology and AI.

VHT pays a quarterly dividend. The most recent distribution of $0.994 per share was paid in late March 2026. The fund’s trailing yield sits near 1.4%, modest but consistent, and dividend amounts have grown over several years, though payments vary quarter to quarter rather than following a smooth upward path.

The Tradeoffs Worth Understanding

1. Concentration at the top creates single-stock sensitivity. With Eli Lilly alone representing over 12% of the fund, a setback from a clinical trial failure, pricing legislation, or competitive pressure ripples through the entire portfolio. Investors aren’t just buying “healthcare” broadly; they’re making a meaningful implicit bet on a handful of mega-cap names.
2. Regulatory risk is structural, not temporary. Drug pricing legislation, Medicare negotiation rules, and insurance market reforms directly affect VHT’s largest holdings. Healthcare is one of the few sectors where government policy can reprice entire business models almost overnight.
3. The defensive label has limits. VHT has underperformed the broad market across both the five-year and ten-year windows, meaning investors who used it as a core holding left real returns on the table. It cushions drawdowns in some environments but doesn’t eliminate market risk.

Where This Fund Earns Its Place

VHT is structured as a tactical sector sleeve for investors who want dedicated healthcare exposure without picking individual stocks, and allocations in that range are common in diversified portfolios. Aging populations globally drive sustained demand for pharmaceuticals, devices, and services regardless of economic conditions. For investors who already hold a broad market fund and want to tilt toward healthcare’s structural growth story, VHT delivers that exposure at minimal cost with genuine diversification across the sector’s sub-industries.

VHT offers clean, low-cost healthcare sector exposure as part of a diversified portfolio, though the sector’s recent decade of underperformance raises the question of whether that gap reflects a temporary cycle or a more durable structural constraint.